» Articles » PMID: 37997613

Model Validation and Selection in Metabolic Flux Analysis and Flux Balance Analysis

Overview
Journal Biotechnol Prog
Date 2023 Nov 24
PMID 37997613
Authors
Affiliations
Soon will be listed here.
Abstract

13C-Metabolic Flux Analysis (13C-MFA) and Flux Balance Analysis (FBA) are widely used to investigate the operation of biochemical networks in both biological and biotechnological research. Both methods use metabolic reaction network models of metabolism operating at steady state so that reaction rates (fluxes) and the levels of metabolic intermediates are constrained to be invariant. They provide estimated (MFA) or predicted (FBA) values of the fluxes through the network in vivo, which cannot be measured directly. These fluxes can shed light on basic biology and have been successfully used to inform metabolic engineering strategies. Several approaches have been taken to test the reliability of estimates and predictions from constraint-based methods and to compare alternative model architectures. Despite advances in other areas of the statistical evaluation of metabolic models, such as the quantification of flux estimate uncertainty, validation and model selection methods have been underappreciated and underexplored. We review the history and state-of-the-art in constraint-based metabolic model validation and model selection. Applications and limitations of the χ -test of goodness-of-fit, the most widely used quantitative validation and selection approach in 13C-MFA, are discussed, and complementary and alternative forms of validation and selection are proposed. A combined model validation and selection framework for 13C-MFA incorporating metabolite pool size information that leverages new developments in the field is presented and advocated for. Finally, we discuss how adopting robust validation and selection procedures can enhance confidence in constraint-based modeling as a whole and ultimately facilitate more widespread use of FBA in biotechnology.

Citing Articles

Metabolic models predict fotemustine and the combination of eflornithine/rifamycin and adapalene/cannabidiol for the treatment of gliomas.

Kishk A, Pacheco M, Heurtaux T, Sauter T Brief Bioinform. 2024; 25(3).

PMID: 38701414 PMC: 11066901. DOI: 10.1093/bib/bbae199.

References
1.
Yu King Hing N, Aryal U, Morgan J . Probing Light-Dependent Regulation of the Calvin Cycle Using a Multi-Omics Approach. Front Plant Sci. 2021; 12:733122. PMC: 8521058. DOI: 10.3389/fpls.2021.733122. View

2.
Santos-Merino M, Gargantilla-Becerra A, de la Cruz F, Nogales J . Highlighting the potential of PCC 7942 as platform to produce α-linolenic acid through an updated genome-scale metabolic modeling. Front Microbiol. 2023; 14:1126030. PMC: 10043229. DOI: 10.3389/fmicb.2023.1126030. View

3.
Theorell A, Leweke S, Wiechert W, Noh K . To be certain about the uncertainty: Bayesian statistics for C metabolic flux analysis. Biotechnol Bioeng. 2017; 114(11):2668-2684. DOI: 10.1002/bit.26379. View

4.
Sundqvist N, Grankvist N, Watrous J, Mohit J, Nilsson R, Cedersund G . Validation-based model selection for 13C metabolic flux analysis with uncertain measurement errors. PLoS Comput Biol. 2022; 18(4):e1009999. PMC: 9022838. DOI: 10.1371/journal.pcbi.1009999. View

5.
Lieven C, Beber M, Olivier B, Bergmann F, Ataman M, Babaei P . MEMOTE for standardized genome-scale metabolic model testing. Nat Biotechnol. 2020; 38(3):272-276. PMC: 7082222. DOI: 10.1038/s41587-020-0446-y. View